Carlisle Companies Incorporated (CSL)

Interest coverage

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 1,039,100 1,065,900 1,060,700 1,188,300 1,316,100 1,218,200 1,066,700 792,400 600,400 529,200 488,900 467,800 478,200 508,200 546,100 638,500 663,100 636,400 584,900 535,000
Interest expense (ttm) US$ in thousands 3,000 -7,800 -4,600 -900 2,900 11,000 8,200 4,900 1,500 1,700 1,000 1,500 1,200 9,300 6,900 3,800 1,200 2,600 2,200 -200
Interest coverage 346.37 453.83 110.75 130.09 161.71 400.27 311.29 488.90 311.87 398.50 54.65 79.14 168.03 552.58 244.77 265.86

December 31, 2023 calculation

Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $1,039,100K ÷ $3,000K
= 346.37

The interest coverage ratio of Carlisle Companies Inc. has shown a strong and consistent increasing trend over the past eight quarters, indicating the company's improving ability to cover its interest expense from its operating income. The ratio has steadily increased from 9.09 in Q1 2022 to 17.66 in Q4 2023.

This upward trend suggests that Carlisle Companies Inc. has been able to generate significantly more operating income relative to its interest expenses. The substantial improvement in interest coverage ratio signifies the company's enhanced financial health and decreased risk of defaulting on its debt obligations.

The consistent and robust interest coverage ratios reflect Carlisle Companies Inc.'s strong operational performance and financial management, demonstrating the company's capacity to comfortably meet its interest payments and potentially pursue further growth opportunities.


Peer comparison

Dec 31, 2023

Company name
Symbol
Interest coverage
Carlisle Companies Incorporated
CSL
346.37
West Pharmaceutical Services Inc
WST
80.52